Anika Therapeutics (NSDQ:ANIK) has inked a deal to extend its two-year-long collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst.
The group plans to focus its efforts on developing a novel therapeutic candidate to treat rheumatoid arthritis. Anika and UMass reported that it hopes to bring the product into clinical trials to support a potential regulatory submission.
Get the full story at our sister site, Drug Delivery Business News.
The post Anika extends deal with UMass Amherst to develop rheumatoid arthritis therapy appeared first on MassDevice.